Your browser doesn't support javascript.
loading
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen, Guo; McQuade, Jennifer L; Panka, David J; Hudgens, Courtney W; Amin-Mansour, Ali; Mu, Xinmeng Jasmine; Bahl, Samira; Jané-Valbuena, Judit; Wani, Khalida M; Reuben, Alexandre; Creasy, Caitlyn A; Jiang, Hong; Cooper, Zachary A; Roszik, Jason; Bassett, Roland L; Joon, Aron Y; Simpson, Lauren M; Mouton, Rosalind D; Glitza, Isabella C; Patel, Sapna P; Hwu, Wen-Jen; Amaria, Rodabe N; Diab, Adi; Hwu, Patrick; Lazar, Alexander J; Wargo, Jennifer A; Garraway, Levi A; Tetzlaff, Michael T; Sullivan, Ryan J; Kim, Kevin B; Davies, Michael A.
Afiliação
  • Chen G; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • McQuade JL; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Panka DJ; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Hudgens CW; Departments of Pathology and Translational and Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Amin-Mansour A; Broad Institute, Cambridge, Massachusetts.
  • Mu XJ; Broad Institute, Cambridge, Massachusetts.
  • Bahl S; Broad Institute, Cambridge, Massachusetts.
  • Jané-Valbuena J; Broad Institute, Cambridge, Massachusetts.
  • Wani KM; Departments of Pathology and Translational and Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Reuben A; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston7Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Creasy CA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Jiang H; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston7Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Cooper ZA; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston7Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Roszik J; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Bassett RL; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
  • Joon AY; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
  • Simpson LM; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Mouton RD; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Glitza IC; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Patel SP; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Hwu WJ; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Amaria RN; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Diab A; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Hwu P; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Lazar AJ; Departments of Pathology and Translational and Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Wargo JA; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston7Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Garraway LA; Broad Institute, Cambridge, Massachusetts.
  • Tetzlaff MT; Departments of Pathology and Translational and Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Sullivan RJ; Massachusetts General Hospital, Boston.
  • Kim KB; California Pacific Medical Center Research Institute, San Francisco.
  • Davies MA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston11Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston.
JAMA Oncol ; 2(8): 1056-64, 2016 Aug 01.
Article em En | MEDLINE | ID: mdl-27124486
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Sistema de Sinalização das MAP Quinases / Inibidores de Proteínas Quinases / Melanoma / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JAMA Oncol Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Sistema de Sinalização das MAP Quinases / Inibidores de Proteínas Quinases / Melanoma / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JAMA Oncol Ano de publicação: 2016 Tipo de documento: Article